News

Researchers noted growing evidence supporting an additional role for B vitamins.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how eye and brain vascular events such as retinal vein occlusion and stroke can signal antiphospholipid syndrome and require further evaluation.

New SOL-X extension follows AXPAXLI implant in wet AMD for 3 years, probing 24-week dosing durability, safety and vision protection.

According to the company, the NDA submission is supported by data from the phase 3 DRAGON trial.

Melding ophthalmology and neurology

New expert‑led series explores how ophthalmic innovations move from early development to market‑ready therapies through cross‑functional collaboration.

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

The company noted it expects topline results in June 2026.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.

Zaman discusses the positive topline results from a phase 1/2 study of the BIM-IOL system, during which it successfully reduced IOP in patients with OAG or OHT.

An analysis of lifitegrast trial subgroups showed that earlier treatment and milder baseline disease were associated with faster and greater symptom improvement.

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision endpoints.

SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.

Combining peristaltic and Venturi pump technology during phacoemulsification may reduce ultrasound time and support endothelial preservation.

An ophthalmology resident shares insights from experiences across Mexico, Europe, and the US.

Darovasertib–crizotinib extends PFS and drives 37% responses in HLA-A*02:01-negative metastatic uveal melanoma, paving path to approval.

Dan B. Tran, MD, compared refractive accuracy, cylinder correction, and postoperative adjustment rates between femtosecond laser–assisted and manual capsulotomy in Light Adjustable Lens cases.

The trial will evaluate EC-104 fluocinolone acetonide (FA) extended release for the treatment of diabetic macular edema (DME).

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

Mt. Sinai to introduce the miDOC system at the ASCRS annual meeting

George O. Waring IV, MD, FACS, discussed how “tolerance” may expand the QRS functional vision model, with new data on IOL performance in residual astigmatism and defocus.